Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Drug Drug Interaction
Interventions: Fruquintinib, Itraconazole, Rifampin; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Colorectal Cancer
Interventions: Right time eating, Delayed time eating, Sigmoidoscopy, Optional 24h circadian assessment in the Biological Rhythms lab, Alcohol; Other · Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 21 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seizures
Interventions: Levetiracetam; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: PF-06826647 or Placebo, PF-06826647; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 13 more

Conditions: Healthy Volunteers
Interventions: SHP643; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Subjects, Pharmacokinetics of YM178
Interventions: YM178 OCAS, Ketoconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cancer
Interventions: SOR-C13; Drug
Lead sponsor: Soricimed Biopharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: Quantitative Interview, Ethnographic Interview, Gender Interview; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 23 Years · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 30
States / cities: Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Low Back Pain, Patient Acceptance of Health Care, Veterans Health
Interventions: Chiropractic Care; Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • West Haven, Connecticut • Iowa City, Iowa + 1 more

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Stress, Cancer Diagnosis, Distress, Emotional
Interventions: Smart-3RP, Enhanced Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dementia
Interventions: Active Caregiving: Enhancing Skills; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Saline, PF-02545920, Ketamine, Placebo; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: HIV/AIDS, Sexually Transmitted Infections
Interventions: RESPECT-2 Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 5,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more

Conditions: Epilepsy
Interventions: Mangafodipir, Gadolinium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Vascular Diseases, Cardiovascular Diseases
Interventions: Group mediated cognitive behavioral (GMCB) sessions, Health education sessions; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 25 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes, Obesity
Interventions: Group Lifestyle Program, Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gulf War Veteran's Illness
Interventions: Tai Chi Intervention, Wellness Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Caregivers
Interventions: Earkick app; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia
Interventions: placebo, SEP-363856, metformin; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oakland Park, Florida • Marlton, New Jersey

Conditions: Hyperphosphatemia, End-Stage Renal Disease
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 15
States / cities: Westminster, Colorado • Pembroke Pines, Florida • Augusta, Georgia + 10 more

Search by objective public record fields.

Fruquintinib CYP3A Inhibitor and Inducer Study

Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis

Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

Engaging Care for HIV-infected Adolescent Females.

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Veterans Response to Dosage in Chiropractic Therapy

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Building Resiliency Among Caregivers of Curvivors and Metavivors

The Black Immigrant Project

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])

Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study

Novel Interventions for GWVI

Supporting Care Partners' Well-Being With Artificial Intelligence (AI) Chatbots

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease